NOTICIA
18.05.2026Resumen IA
India Denies Secondary Patent for AbbVie's Hepatitis C Drug Maviret
The Indian Patent Office denied AbbVie a secondary patent for its Hepatitis C drug Maviret, ensuring affordable treatment access for millions. AbbVie abandoned its application after failing to contest oppositions.
E
Economic Times